CONMED (CNMD) Competitors $71.23 -0.09 (-0.13%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CNMD vs. GKOS, BLCO, INSP, PRCT, AXNX, NVCR, NVST, NARI, IRTC, and LIVNShould you be buying CONMED stock or one of its competitors? The main competitors of CONMED include Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Axonics (AXNX), NovoCure (NVCR), Envista (NVST), Inari Medical (NARI), iRhythm Technologies (IRTC), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. CONMED vs. Glaukos Bausch + Lomb Inspire Medical Systems PROCEPT BioRobotics Axonics NovoCure Envista Inari Medical iRhythm Technologies LivaNova Glaukos (NYSE:GKOS) and CONMED (NYSE:CNMD) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk. Does the MarketBeat Community believe in GKOS or CNMD? Glaukos received 410 more outperform votes than CONMED when rated by MarketBeat users. Likewise, 64.72% of users gave Glaukos an outperform vote while only 47.22% of users gave CONMED an outperform vote. CompanyUnderperformOutperformGlaukosOutperform Votes44464.72% Underperform Votes24235.28% CONMEDOutperform Votes3447.22% Underperform Votes3852.78% Is GKOS or CNMD more profitable? CONMED has a net margin of 10.23% compared to Glaukos' net margin of -42.43%. CONMED's return on equity of 13.84% beat Glaukos' return on equity.Company Net Margins Return on Equity Return on Assets Glaukos-42.43% -18.99% -11.47% CONMED 10.23%13.84%5.26% Which has more risk and volatility, GKOS or CNMD? Glaukos has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, CONMED has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Do analysts rate GKOS or CNMD? Glaukos presently has a consensus price target of $143.17, indicating a potential downside of 2.18%. CONMED has a consensus price target of $79.80, indicating a potential upside of 12.03%. Given CONMED's higher possible upside, analysts plainly believe CONMED is more favorable than Glaukos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Glaukos 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.85CONMED 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media refer more to GKOS or CNMD? In the previous week, Glaukos had 17 more articles in the media than CONMED. MarketBeat recorded 18 mentions for Glaukos and 1 mentions for CONMED. CONMED's average media sentiment score of 1.05 beat Glaukos' score of 0.87 indicating that CONMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 9 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CONMED 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of GKOS or CNMD? 99.0% of Glaukos shares are owned by institutional investors. 6.4% of Glaukos shares are owned by insiders. Comparatively, 6.8% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has stronger earnings & valuation, GKOS or CNMD? CONMED has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlaukos$360.35M22.39-$134.66M-$3.02-48.46CONMED$1.29B1.71$64.46M$4.2116.92 SummaryCONMED beats Glaukos on 11 of the 19 factors compared between the two stocks. Ad WealthPressIs the Trump/Musk duo good for shares of TSLA?If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get CONMED News Delivered to You Automatically Sign up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNMD vs. The Competition Export to ExcelMetricCONMEDElectromedical equipment IndustryMedical SectorNYSE ExchangeMarket Cap$2.20B$3.04B$5.13B$19.60BDividend Yield1.10%1.73%4.74%3.50%P/E Ratio16.9217.38134.7943.92Price / Sales1.7154.941,255.7117.46Price / Cash12.1139.9140.4121.72Price / Book2.633.754.905.46Net Income$64.46M$87.97M$117.74M$986.21M7 Day Performance-4.71%-3.88%14.56%-2.12%1 Month Performance-1.40%-0.79%17.54%1.30%1 Year Performance-37.06%8.62%36.48%16.47% CONMED Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNMDCONMED4.6148 of 5 stars$71.23-0.1%$79.80+12.0%-37.0%$2.20B$1.29B16.924,000Positive NewsGKOSGlaukos4.0782 of 5 stars$144.20+3.8%$143.17-0.7%+76.9%$7.95B$360.35M-46.00780Short Interest ↓BLCOBausch + Lomb2.2605 of 5 stars$18.61+0.1%$20.58+10.6%+22.3%$6.55B$4.68B-17.7113,300Short Interest ↑INSPInspire Medical Systems4.6941 of 5 stars$188.38+0.3%$233.58+24.0%+0.4%$5.65B$755.59M176.781,011Short Interest ↓Positive NewsPRCTPROCEPT BioRobotics3.0552 of 5 stars$90.19+1.1%$97.86+8.5%+106.0%$4.71B$136.19M0.00626Positive NewsAXNXAxonics1.1659 of 5 stars$70.98+0.8%$71.00+0.0%+21.8%$3.63B$366.38M-591.45610High Trading VolumeNVCRNovoCure2.8683 of 5 stars$32.91-1.5%$32.67-0.7%+134.1%$3.56B$577.74M-23.861,453NVSTEnvista3.621 of 5 stars$19.56+0.5%$20.65+5.6%-17.9%$3.37B$2.50B-2.5112,800Positive NewsNARIInari Medical2.5692 of 5 stars$55.67+0.1%$58.89+5.8%-12.6%$3.26B$574.50M-41.181,300Analyst ForecastNews CoverageIRTCiRhythm Technologies2.8808 of 5 stars$90.08+4.2%$107.82+19.7%-10.5%$2.82B$492.68M-17.782,000LIVNLivaNova3.9507 of 5 stars$50.01-2.9%$69.17+38.3%+0.2%$2.72B$1.24B122.622,900Positive News Related Companies and Tools Related Companies GKOS Competitors BLCO Competitors INSP Competitors PRCT Competitors AXNX Competitors NVCR Competitors NVST Competitors NARI Competitors IRTC Competitors LIVN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CNMD) was last updated on 12/17/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CONMED Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CONMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
